RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs - Seite 3

While our AMPAkines have demonstrated positive clinical effects in treating attention deficit hyperactivity disorder (ADHD) and opioid induced respiratory depression, they have not yet been tested in in patients with SCI and there can be no assurance that such tests will be successful.

ResolutionRx

Dronabinol

RespireRx’s business unit, ResolutionRx has been utilizing nanotechnological approaches to develop a number of new potential formulations of dronabinol, Δ9-THC. After extensive bench testing, several have been identified for additional testing for selection of lead and secondary formulations, before commencing the required animal pharmacokinetic and pharmacodynamic (“PK/PD”) studies that are currently being designed. These formulations are intended to improve the PK/PD profile of dronabinol for an all-night indication such as obstructive sleep apnea, our initial targeted indication.

None of these formulations have yet been tested in humans and there can be no assurance that such tests if conducted, will be successful.

About RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is a leader in the discovery and development of medicines for the treatment of psychiatric and neurological disorders, with a focus on treatment options that address conditions affecting millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”), epilepsy, chronic pain and recovery from spinal cord injury (“SCI”), as well as certain neurological orphan diseases. RespireRx is developing a pipeline of new drug products based on our broad patent portfolios for two drug platforms: (i) pharmaceutical cannabinoids, which include dronabinol, a synthetic form of ∆9-tetrahydrocannabinol (“Δ9-THC”) that acts upon the nervous system’s endogenous cannabinoid receptors and (ii) neuromodulators, which include AMPAkines and GABAkines, proprietary compounds that positively modulate (positive allosteric modulators or “PAMs”) AMPA-type glutamate receptors and GABA_A receptors, respectively

The Company holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.

ResolutionRx: Pharmaceutical Cannabinoids. 

RespireRx is developing dronabinol, ∆-9-THC, a synthetic version of the naturally occurring substance in the cannabis plant, for the treatment of OSA, a serious respiratory disorder that impacts an estimated 29.4 million people in the United States according to the American Academy of Sleep Medicine (“AASM”), published in August 2016. OSA has been linked to increased risk for hypertension, heart failure, depression, and diabetes, and has an annual economic cost in the United States of $162 billion according to the AASM. There are no approved drug treatments for OSA.